SCHEMBL1476003

SCHEMBL1476003

O=C(O)c1cccc2ccsc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.48
NR4A1 P22736 1/20 0.48
NR4A2 P43354 1/20 0.48
NR4A3 Q92570 1/20 0.48
HSD17B10 Q99714 1/20 0.47
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ALDH1A1 P00352 3/20 0.44
ALOX15 P16050 2/20 0.44
CDC25B P30305 1/20 0.43
KEAP1 Q14145 1/20 0.43
HDAC4 P56524 1/20 0.43
PTPN1 P18031 1/20 0.42
LMNA P02545 1/20 0.42
AKR1C3 P42330 1/20 0.41
PIM1 P11309 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
PIM2 Q9P1W9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476821 0.82 CYP2A6 (0.47) CYP2A6HSD17B10HDAC1HDAC8HDAC6
SCHEMBL3793757 0.82 CYP2A6 (0.47) CYP2A6NR4A1NR4A2NR4A3HDAC1
SCHEMBL6234107 0.82 CYP2A6 (0.47) CYP2A6NR4A1NR4A2NR4A3HSD17B10
SCHEMBL20954578 0.78 PLA2G2D (0.45) CYP2A6HDAC1HDAC8HDAC6HDAC4
SCHEMBL22951423 0.78 CYP2A6 (0.43) CYP2A6HDAC1HDAC8HDAC6HDAC4
SCHEMBL5799568 0.78 PLK1 (0.54) CYP2A6HSD17B10HDAC1HDAC8HDAC6
SCHEMBL6327434 0.78 CYP2A6 (0.43) CYP2A6HSD17B10HDAC1HDAC8HDAC6
SCHEMBL22951424 0.78 CYP2A6 (0.43) CYP2A6HDAC1HDAC8HDAC6ALDH1A1
SCHEMBL2084218 0.78 TSHR (0.46) CYP2A6HSD17B10HDAC1HDAC8HDAC6
SCHEMBL6329409 0.75 CYP2A6 (0.41) CYP2A6HDAC1HDAC8HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955549-A Method for dehydrogenating and coupling silicon and aromatic heterocyclic compound and application thereof 中山大学 2024-11-15 CN claimed
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US claimed
EP-2094690-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-09-02 EP claimed
WO-2008081399-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-07-10 WO claimed
EP-0294292-B1 Derivative of benzo[b]thiophene-7-carboxylic acid, process for its preparation and pharmaceutical compositions containing it ADIR ET COMPAGNIE (FR) 1991-10-09 EP claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-02-20 US disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
CN-109069514-B Antibacterial compound and application thereof 结核病药物开发全球联盟公司 2023-12-29 CN disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
WO-2023121939-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-06-29 WO disclosed
US-6069166-A INHIBITORY ACTIVITY AGAINST INFILTRATION OF EOSIONOPHILS, AND ARE USEFUL AS DRUGS FOR TREATING NASAL BLOCKAGE SHIONOGI & CO., LTD. (JP) 2000-05-30 US disclosed
EP-0945450-A1 FUSED HETEROCYCLIC BENZENECARBOXYLIC ACID AMIDE DERIVATIVES AND PGD2 ANTAGONISTS CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 1999-09-29 EP disclosed
EP-0664806-A1 HETEROCYCLIC CONDENSED BENZOIC ACID DERIVATIVES AS 5-HT 4? RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-08-02 EP disclosed
CN-1092421-A Medicine SMITHKLINE BEECHAM PLC (GB) 1994-09-21 CN disclosed
WO-1994008995-A1 HETEROCYCLIC CONDENSED BENZOIC ACID DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-04-28 WO disclosed
US-5068359-A Fungicides of benzothiophene and benzofuran compounds CIBA-GEIGY CORPORATION (US) 1991-11-26 US disclosed
EP-0294292-B1 Derivative of benzo[b]thiophene-7-carboxylic acid, process for its preparation and pharmaceutical compositions containing it ADIR ET COMPAGNIE (FR) 1991-10-09 EP disclosed
EP-0294292-A2 Derivative of benzo[b]thiophene-7-carboxylic acid, process for its preparation and pharmaceutical compositions containing it ADIR ET COMPAGNIE (FR) 1988-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CYP2A6 555/4885NR4A1 722/4885NR4A2 1245/4885
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF SULT1E1, TPMT, SULT1A1 CYP2A6 198/4885NR4A1 526/4885NR4A2 580/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP CYP2A6 747/4885NR4A1 1568/4885NR4A2 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.